Moxifloxacin Hydrochloride Patent Expiration

1. Avelox patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607942 BAYER HLTHCARE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Mar, 2014

(10 years ago)

US5849752 BAYER HLTHCARE Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification
Dec, 2016

(7 years ago)

US6610327 BAYER HLTHCARE Pharmaceutical moxifloxacin preparation
Oct, 2019

(4 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-185) Sep 27, 2019

Market Authorisation Date: 10 December, 1999

Treatment: Method of combating bacteria in a patient

Dosage: TABLET

How can I launch a generic of AVELOX before it's drug patent expiration?
More Information on Dosage

AVELOX family patents

Family Patents

2. Avelox In Sodium Chloride 0.8% In Plastic Container patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607942 BAYER HLTHCARE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Mar, 2014

(10 years ago)

US5849752 BAYER HLTHCARE Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification
Dec, 2016

(7 years ago)

US6548079 BAYER HLTHCARE Moxifloxacin formulation containing common salt
Jul, 2020

(3 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-185) Sep 27, 2019

Market Authorisation Date: 30 November, 2001

Treatment: Method of combating bacteria in a patient

Dosage: SOLUTION

How can I launch a generic of AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Moxeza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607942 HARROW EYE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Mar, 2014

(10 years ago)

US5607942

(Pediatric)

HARROW EYE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Sep, 2014

(9 years ago)

US7671070 HARROW EYE Method of treating ophthalmic infections with moxifloxacin compositions
Sep, 2019

(4 years ago)

US6716830 HARROW EYE Ophthalmic antibiotic compositions containing moxifloxacin
Sep, 2019

(4 years ago)

US6716830

(Pediatric)

HARROW EYE Ophthalmic antibiotic compositions containing moxifloxacin
Mar, 2020

(4 years ago)

US7671070

(Pediatric)

HARROW EYE Method of treating ophthalmic infections with moxifloxacin compositions
Mar, 2020

(4 years ago)

US9114168 HARROW EYE Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
May, 2029

(4 years from now)

US8450311 HARROW EYE Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
May, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 19, 2013
Pediatric Exclusivity(PED) May 19, 2014

Market Authorisation Date: 19 November, 2010

Treatment: Method of combating bacteria in a patient

Dosage: SOLUTION/DROPS

How can I launch a generic of MOXEZA before it's drug patent expiration?
More Information on Dosage

MOXEZA family patents

Family Patents

4. Vigamox patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607942 HARROW EYE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Mar, 2014

(10 years ago)

US5607942

(Pediatric)

HARROW EYE 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
Sep, 2014

(9 years ago)

US7671070 HARROW EYE Method of treating ophthalmic infections with moxifloxacin compositions
Sep, 2019

(4 years ago)

US6716830 HARROW EYE Ophthalmic antibiotic compositions containing moxifloxacin
Sep, 2019

(4 years ago)

US7671070

(Pediatric)

HARROW EYE Method of treating ophthalmic infections with moxifloxacin compositions
Mar, 2020

(4 years ago)

US6716830

(Pediatric)

HARROW EYE Ophthalmic antibiotic compositions containing moxifloxacin
Mar, 2020

(4 years ago)




Market Authorisation Date: 15 April, 2003

Treatment: Method of combating bacteria in a patient

Dosage: SOLUTION/DROPS

How can I launch a generic of VIGAMOX before it's drug patent expiration?
More Information on Dosage

VIGAMOX family patents

Family Patents